강스템바이오텍

217730KOSDAQSector: Pharma & Biotech

₩2,105▼ 2.09%Market cap ₩198.0BAs of Jul 21, 2026 close · updated once daily

Grade D39.5 ptsTop 71% of 2,523 stocks

Financial strength

50.4

Growth momentum

29.4

Price attractiveness

34.2

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

Financial strength

50.4

How much debt does it carry relative to equity?

Debt-to-equity ratio

18.0%

✓ Above median · Top 19.7% in sector

Sector median 51.5%

Can it cover what's due within a year?

Current ratio

525.4%

✓ Above median · Top 25.4% in sector

Sector median 191.3%

How much of revenue becomes profit?

Operating margin

-494.6%

✗ Below median · Top 91.6% in sector

Sector median -2.3%

How much did it earn on its own capital?

ROE (return on equity)

-15.3%

✗ Below median · Top 61.6% in sector

Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

Growth momentum

29.4

Has it grown steadily over three years?

Revenue 3-year CAGR

-39.7%

✗ Below median · Top 95.3% in sector

Sector median 4.9%

Are core profits higher than three years ago?

Operating income change (3Y)

14.1%

✓ Above median · Top 46% in sector

Sector median 3.5%

Source filing: annual report (consolidated) — view original ↗

Price attractiveness

34.2

Is the price expensive relative to earnings?

P/E (price-to-earnings)

Loss-making (P/E not computable)

✗ Below median · Top 62.8% in sector

Sector median P/E of profitable peers 14.4x · 57% loss-making

Is the price expensive relative to book value?

P/B (price-to-book)

2.88x

✗ Below median · Top 68.9% in sector

Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15